

H11

4/5/1

DIALOG(R) File 351:Derwent WPI
(c) 2003 Thomson Derwent. All rts. reserv.

011931111

WPI Acc No: 1998-348021/ 199830

Related WPI Acc No: 1994-293954; 1996-159656; 1997-331543; 1997-332006;
1997-384623; 1997-456762; 1997-469491; 1998-239842; 1999-095455;
2001-061279; 2002-075343

XRAM Acc No: C98-107484

**Delivery of water insoluble bioactive agents as suspended nanoparticles -
by coating agent in organic phase with aqueous protein and/or synthetic
polymer as stabiliser, under high shear, notable use for taxol.**

Patent Assignee: VIVORX PHARM INC (VIVO-N)

Inventor: DESAL N P; LOUIE L; MAGDASSI S; SOON-SHIONG P; TAO C; YANG A; YAO
Z; ZHENG T; DESAI N P

Number of Countries: 080 Number of Patents: 010

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9814174	A1	19980409	WO 97US17157	A	19970924	199830 B
AU 9745929	A	19980424	AU 9745929	A	19970924	199835
NO 9901620	A	19990601	WO 97US17157	A	19970924	199932
			NO 991620	A	19990406	
US 5916596	A	19990629	US 9323698	A	19930222	199932
			US 95412726	A	19950329	
			US 96720756	A	19961001	
EP 961612	A1	19991208	EP 97944429	A	19970924	200002
			WO 97US17157	A	19970924	
CN 1237901	A	19991208	CN 97199720	A	19970924	200016
AU 718753	B	20000420	AU 9745929	A	19970924	200029
NZ 335133	A	20001222	NZ 335133	A	19970924	200104
			WO 97US17157	A	19970924	
JP 2001501931	W	20010213	WO 97US17157	A	19970924	200112
			JP 98516657	A	19970924	
BR 9711856	A	20011106	BR 9711856	A	19970924	200175
			WO 97US17157	A	19970924	

Priority Applications (No Type Date): US 96720756 A 19961001; US 9323698 A
19930222; US 95412726 A 19950329

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9814174 A1 E 71 A61K-009/14

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU
CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
UA UG US UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GR IE IT
KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9745929 A Based on patent WO 9814174

US 5916596 A Div ex application US 9323698

CIP of application US 95412726

Div ex patent US 5439686

CIP of patent US 5560933

EP 961612 A1 E Based on patent WO 9814174

Designated States (Regional): AT BE CH DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

AU 718753 B Previous Publ. patent AU 9745929

Based on patent WO 9814174

NZ 335133 A A61K-009/14 Based on patent WO 9814174

JP 2001501931 W 58 A61K-047/30 Based on patent WO 9814174

BR 9711856 A A61K-009/14 Based on patent WO 9814174

Abstract (Basic): WO 9814174 A

Formulation of a pharmacologically active agent, almost insoluble
in water, for in vivo delivery, comprises subjecting a mixture
comprising: (a) the agent dispersed in an organic phase; and (b)
aqueous medium containing biocompatible polymer; to high shear
conditions in a high pressure homogeniser at a pressure between 3000
and 30000 psi, provided that substantially no surfactants are present;

and, optionally, removing the organic and/or aqueous phase from the mixture. Also claimed is a drug delivery system, comprising particles of a solid or liquid, water insoluble pharmacologically active agent, coated with protein, in which the coating has associated protein; a portion of the active agent is contained within the protein coating, and a portion is associated with the protein; and the average diameter of the particles is not greater than 1 μ .

USE - The formulation produces microparticles, but preferably nanoparticles, i.e., diameter less than 1 micron, of active agent, coated with the biocompatible polymer, suspended in the aqueous phase. These can be injected to provide a pre-programmed release profile, with duration from a few hours to weeks or months from a single dose. Under the high shear conditions, the particles are small enough (less than a few microns) to be safe, without risk of capillary blockage or infarction; smaller sizes (less than 200 nm) can be sterile filtered for injection. The particles may be either crystalline and/or amorphous, with the latter preferred for better bioavailability. A wide variety of active agents, including therapeutic, prophylactic, and diagnostic agents, and agents of nutritional value, can be delivered in the formulation. Examples of therapeutic/prophylactic agents include analgesics, antipyretics, anaesthetics, antiasthmatics, antibiotics, antidepressants, antidiabetics, antifungals, antihypertensives, antiinflammatories, antineoplastics, antianxiety or antimigraine drugs, immunosuppressives, sedatives, hypnotics, antianginals, antipsychotics, antimania or antigout agents, antiarrhythmics, antiarthritics, anticoagulants, thrombolytics, antifibrinolytics, haemorrhagic or antiplatelet agents, antiparkinson or calcium regulatory agents, antihistamines, antipruritics, antimicrobials, antibacterials, antivirals, antiinfectives, bronchodilators, hormones, , hypoglycaemics, hypolipidaemics, proteins, nucleic acids (both sense and antisense to encode proteins), erythropoietin stimulators, antiulcer, antireflux agents, antinauseants, and antiemetics. Most notable are antineoplastics and immunosuppressants; specific antineoplastic examples are adriamycin, cyclophosphamide, actinomycin, bleomycin, daunorubicin, doxorubicin, epirubicin, mitomycin, methotrexate, fluorouracil, cisplatin, carboplatin, carmustine (BCNU), methyl-CCNU, etoposide, pipsulphan, interferon, or camptothecin, taxol (paclitaxel), taxotere, and their derivatives; of immunosuppressants, cyclosporine, azathioprine, mizoribine, and FK506; other drugs noted are mitotane, visadine, halonitrosoureas, anthrocyclines, and ellipticine. Examples of diagnostic agents are contrast agents for ultrasound, radioactives, and magnetic resonance. Examples of nutritional agents include amino acids, sugars, proteins, carbohydrates, fat-soluble vitamins (A, D, E, K), and fats.

ADVANTAGE - Disadvantages of oral administration, including insolubility with low bioavailability, are avoided; also encapsulation protects the drug from liver 'first pass' effects. Surfactants, as used in Cremophor and other prior art dispersants, can have allergic or even toxic side effects, e.g., myelosuppressive, if used in considerable quantities, as required for taxane type antineoplastics, limiting or preventing continuous administration. Many drugs do associate naturally with serum proteins as carriers in the body, particularly serum albumin. The present method avoids surfactants, but allows solutions containing, e.g., more than 1 mg/ml of taxol, resulting in effective total infusion volumes of less than 300 ml. This improves patient compliance; in addition, ability for continuous dosing without breaks minimises hospital stay. When the carrier is biodegradable, as with proteins, no effects are felt from the system.

Dwg.0/2

Title Terms: DELIVER; WATER; INSOLUBLE; BIOACTIVE; AGENT; SUSPENSION;
COATING; AGENT; ORGANIC; PHASE; AQUEOUS; PROTEIN; SYNTHETIC; POLYMER;
STABILISED; HIGH; SHEAR; NOTABLY; TAXOL

Derwent Class: B05; B07; P33

International Patent Class (Main): A61K-009/14; A61K-047/30

International Patent Class (Additional): A61J-003/00; A61K-009/38;

A61K-045/00; A61K-047/48; A61K-049/00; A61P-029/00; A61P-035/00

File Segment: CPI; EngPI